Global Fabry Disease Market 2015-2019

Price :
Published : Nov-2014
No. of Pages : 80

Fabry disease is an inheritable lysosomal storage disease characterized by the excessive accumulation of globotriaosylceramide (GL-3) in lysosomes. It results from a deficiency of a-Gal and can result in symptoms such as fatigue, angiokeratoma, tinnitus, kidney failure, heart disorders, and nervous system problems. Fabry disease results from mutations in the galactosidase (GLA) gene, resulting in decreased activity or complete absence of a-Gal. Fabry disease resulting from the decreased activity of the enzyme is called later-onset Fabry disease. This form of the disease can effect both males and females. The symptoms of this disease typically appear during adulthood and usually focus on a single organ. Fabry disease resulting from the complete absence of a-Gal results in a more severe form called classic Fabry disease. The classic form of the disease usually affects males. The disease symptoms usually starts in adolescence and include clouded eye lenses, skin lesions, pain, and reduced sweating. If untreated, the disease can lead to cardiac dysfunction, renal failure or stroke, often resulting in death during fourth or fifth decade of life.

TechNavio’s analysts forecast the Global Fabry Disease market to grow at a CAGR of 18.08 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Fabry Disease market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various innovator drugs available in the market for the treatment of fabry disease.

TechNavio’s report, the Global Fabry Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Fabry Disease market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Genzyme
  • Shire

Other Prominent Vendors

  • Amicus Therapeutics
  • Green Cross Corporation
  • ISU Abxis
  • JCR Pharmaceuticals
  • Protalix Biotherapeutics

Market Driver

  • Special Provisions for Orphan Drugs
  • For a full, detailed list, view our report

Market Challenge

  • Limited Patient Population
  • For a full, detailed list, view our report

Market Trend

  • Regulatory Assistance in Emerging Countries
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical, Therapeutics
Publisher : Technavio
More Reports
Title Price Buy Now

Banner Health – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Banner Health (Banner) is a nonprofit health care system that offers hospital care, hospice care, nursing registries, surgery center, laboratories and rehabilitation services. It also provides community-based social service programs and health-related educational programs. The organization owns and leases clinics, hospitals, clinical laboratories, nursing homes, home health agencies, ambulatory surgery centers, and manages other healthcare related companies such as health insurance companies. Banner operates through a network of medical centers, institutes, concussion centers, health centers, health clinics, research institutes, children's medical center, laboratories, occupational health centers, senior centers and residences, surgery centers, and urgent care centers. It serves i......

Community Health Systems Inc (CYH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Community Health Systems Inc. (CHS) is an operator of general acute care hospitals and outpatient facilities in communities. The company's services include general acute care services, emergency room services, general and specialty surgery, critical care, internal medicine, obstetrics and diagnostic services, psychiatric and rehabilitation services. CHS also provides outpatient services through its urgent care centers, cancer centers, ambulatory surgery centers, occupational medicine clinics, imaging centers and home health and hospice agencies. It owns, leases or operates hospitals, through which it offers healthcare services in non-urban and selected urban markets in the US. CHS has hospitals in various states in the US. CHS is headquartered in Franklin, Tennessee, the US. Comm......

Keryx Biopharmaceuticals Inc (KERX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company's lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based phosphate binder, which helps lower the amount of phosphate in human blood. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric (ferric citrate coordination complex). The company has subsidiaries and offices in Israel, the US, and the UK. Keryx is headquartered in New York, the US. Keryx Biopharmaceuticals Inc (KERX) - Pharmaceuticals & Healthcare - Deals and Alliances P......

Lonza Group Ltd (LONN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic personal care ingredients. It also provides custom development and custom manufacturing services to its clients. Lonza's client base includes professionals in the biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; distributors; formulators and service companies. The company's key markets include bioresearch, nutrition, pharma and biotech, microbial ......

MallInckrodt Plc (MNK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Mallinckrodt Plc (Mallinckrodt) is a healthcare products provider that offers generics and active pharmaceutical ingredients. The company offers generic products which include addiction treatment products, compounding powders, unit dose products and resource tool kits. Its active pharmaceutical ingredients comprise acetaminophen and paracetamol; controlled substances and stearates. Mallinckrodt offers nuclear imaging; contrast media and other medical imaging devices. The company also offers contrast media and devices which include advanced integrated softwares, imaging systems, prefilled syringes and others. It markets its products in the UK and abroad. Mallinckrodt is headquartered in Surrey, the UK. MallInckrodt Plc (MNK) - Pharmaceuticals & Healthcare - Deals and Alliances Pro......

Insulet Corp (PODD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes OmniPod insulin management system, an insulin infusion system for diabetic patients. OmniPod insulin management system consists of OmniPod, a disposable insulin infusion device and the Personal Diabetes Manager, a handheld wireless device. Its OmniPod is a tubeless insulin pump that has two parts and a fully-automated cannula insertion. The company's delivery systems business collaborates with several global pharmaceutical and biotechnology companies to adapt the OmniPod technology platform for the delivery of subcutaneous drugs across various therapeutic areas. The company markets its products in the US, Europe, and Asia through direct sales and distribution partners. Insulet is headqua......

Asahi Kasei Pharma Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescription drugs are used for the treatment of osteoporosis pain, disseminated intravascular coagulation, bone loss, dysuria accompanying benign prostatic hyperplasia, nocturia, proteinuria in nephrotic syndrome and lupus nephritis, and difficulty in urination. Asahi Kasei Pharma offers assay kits that determine glycemic control and detect prediabetes. The company's pipeline includes candidates for acute exacerbation of idiopathic pulmonary fibrosis; chemotherapy-induced peripheral neuropathy; oste......

CTI BioPharma Corp (CTIC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company's lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in Europe and the US. CTI BioPharma is headquartered in Seattle, Washington, the US. CTI BioPharma Corp (CTIC) - Pharmaceuticals & Healthcare - Deals and Al......

Active Biotech AB (ACTI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Active Biotech AB (Active Biotech) is a biotechnology company that undertakes the development and commercialization of pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company has five projects in clinical development of which three have been licensed out. Its key products in development include Laquinimod (neurodegenerative diseases); Anyara (cancer); Tasquinimod (cancer); Paquinimod (Systemic Sclerosis); and SILC (autoimmune diseases). Its operations are principally focused on the laquinimod projects, which are focused on the treatment of neurodegenerative/inflammatory diseases. Active Biotech has licensing agreements with Teva Pharmaceutical Industries, NeoTX, Ipsen, Teva Neuroscience and MediGene AG. Active Biotech is headquartered in Lun......

Intas Pharmaceuticals Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and markets pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma derived product based therapies. It has nine formulation manufacturing facilities and two active pharmaceutical ingredient (API) and intermediate facilities in India. The company markets its products globally through i......